BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Near Add Your Location

Sorting 12 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
  • Show Principal Investigator
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
  • Show Principal Investigator
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
  • Accepting patients
Sarah Cannon Research Institute at Tennessee Oncology
TriStar Centennial Medical Center
Nashville, TN
  • Not yet accepting
125 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 354-2873

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.